Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive breast cancer. With a median progression-free survival of 17.3 months and ...

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach ...

Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy. We conducted ...

This is part of the government’s broader effort to improve healthcare accessibility and support patients in need, according ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...